Key Points
- Director Shawn Tomasello purchased 22,725 shares at an average of $2.21 per share (≈$50,222) on Jan. 21, bringing his direct holding to those shares per the SEC filing.
- Broad insider buying — including CEO Steven Nichtberger (45,000 shares at ≈$2.24) and multiple directors/executives buying in the ~$2.19–$2.28 range — indicates aligned bullish sentiment from management and the board.
- Company outlook — Cabaletta is a clinical‑stage biotech developing CAAR‑T therapies for B‑cell autoimmune diseases, targeting a potential FDA filing around 2027, and carries a consensus "Moderate Buy" analyst rating with an average price target of $16.25.
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) General Counsel Michael Gerard bought 6,600 shares of the stock in a transaction on Wednesday, January 21st. The stock was purchased at an average cost of $2.27 per share, with a total value of $14,982.00. Following the completion of the purchase, the general counsel directly owned 6,600 shares in the company, valued at $14,982. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Cabaletta Bio Stock Performance
Shares of CABA stock opened at $2.34 on Thursday. The firm has a market capitalization of $225.25 million, a price-to-earnings ratio of -0.92 and a beta of 3.25. Cabaletta Bio, Inc. has a one year low of $0.99 and a one year high of $3.67. The company has a 50 day moving average price of $2.29 and a 200 day moving average price of $2.11.
Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.05. As a group, equities analysts forecast that Cabaletta Bio, Inc. will post -2.34 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Cabaletta Bio in a report on Friday, October 10th. Cantor Fitzgerald raised their price target on Cabaletta Bio from $15.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, October 31st. Jefferies Financial Group initiated coverage on shares of Cabaletta Bio in a research report on Friday, October 10th. They set a "buy" rating and a $14.00 price target for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cabaletta Bio in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $16.25.
View Our Latest Analysis on CABA
Key Headlines Impacting Cabaletta Bio
Here are the key news stories impacting Cabaletta Bio this week:
- Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average $2.24/share (≈$100,800), increasing his stake to ~1.03M shares — a meaningful insider buy from the company’s top executive. SEC filing
- Positive Sentiment: Director Mark Simon acquired 11,061 shares at ~$2.28/share (~$25.2K), an 8.12% increase in his holding to ~147K shares. SEC filing
- Positive Sentiment: General Counsel Michael Gerard bought 6,600 shares at $2.27/share (~$15K), initiating a new disclosed holding. SEC filing
- Positive Sentiment: Other insiders (director Shawn Tomasello, insider Steve Gavel, Gwendolyn Binder, David J. Chang) executed purchases ranging ~8.8K–22.7K shares at ~$2.19–$2.27 each, many representing large % increases in their positions — broad insider participation suggests aligned bullish views across management and the board. SEC filings
- Positive Sentiment: Report: Cabaletta is accelerating its autoimmune CAR‑T program and is targeting a 2027 FDA filing — a multi‑year development path but one that, if achieved, would be value‑creating. Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates
Institutional Investors Weigh In On Cabaletta Bio
Several hedge funds have recently made changes to their positions in CABA. Bain Capital Life Sciences Investors LLC grew its position in Cabaletta Bio by 250.5% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company's stock worth $14,709,000 after purchasing an additional 6,916,237 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Cabaletta Bio in the second quarter worth $3,036,000. Jennison Associates LLC grew its holdings in shares of Cabaletta Bio by 147.4% during the second quarter. Jennison Associates LLC now owns 6,020,167 shares of the company's stock valued at $9,151,000 after buying an additional 3,586,439 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in shares of Cabaletta Bio during the second quarter valued at $32,000. Finally, Tower Research Capital LLC TRC raised its position in Cabaletta Bio by 695.6% during the second quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company's stock valued at $78,000 after buying an additional 44,621 shares during the period.
About Cabaletta Bio
(
Get Free Report)
Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.
The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
